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Abstract
IFN-a/b plays a critical role in limiting viral spread, restricting viral tropism and protecting mice from neurotropic coronavirus
infection. However, the IFN-a/b dependent mechanisms underlying innate anti-viral functions within the CNS are poorly
understood. The role of RNase L in viral encephalomyelitis was explored based on its functions in inhibiting translation,
inducing apoptosis, and propagating the IFN-a/b pathway through RNA degradation intermediates. Infection of RNase L
deficient (RL
2/2) mice with a sub-lethal, demyelinating mouse hepatitis virus variant revealed that the majority of mice
succumbed to infection by day 12 p.i. However, RNase L deficiency did not affect overall control of infectious virus, or
diminish IFN-a/b expression in the CNS. Furthermore, increased morbidity and mortality could not be attributed to altered
proinflammatory signals or composition of cells infiltrating the CNS. The unique phenotype of infected RL
2/2 mice was
rather manifested in earlier onset and increased severity of demyelination and axonal damage in brain stem and spinal cord
without evidence for enhanced neuronal infection. Increased tissue damage coincided with sustained brain stem infection,
foci of microglia infection in grey matter, and increased apoptotic cells. These data demonstrate a novel protective role for
RNase L in viral induced CNS encephalomyelitis, which is not reflected in overall viral control or propagation of IFN-a/b
mediated signals. Protective function is rather associated with cell type specific and regional restriction of viral replication in
grey matter and ameliorated neurodegeneration and demyelination.
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Introduction
Type I interferon (IFN-a/b) induced anti-viral responses are
critical for the initial control of most virus infections. Although
anti-viral responses are initiated in infected cells, they act in an
autocrine and paracrine fashion, antagonizing virus replication in
host cells and inducing a protective anti-viral state in neighboring
cells. The anti-viral state is distinguished by the expression of
numerous IFN stimulated genes (ISG), which directly or indirectly
interfere with both viral and host RNA transcription and
translation [1]. Many of these pathways can also result in the
apoptosis of infected cells [2]. Nevertheless, the relative contribu-
tions of these various anti-viral effector mechanisms to overall
virus control differ with the virus as well as the tissue and cell type
infected.
The best characterized anti-viral mechanisms are mediated by
activation of double-stranded RNA-dependent protein kinase
(PKR) and the 29-59-oligoadenylatesynthase (OAS)/ribonuclease
L (RNase L) pathways [3–5]. Upon recognition of double-stranded
RNA, the OAS family of proteins convert ATP into unique,
unstable 29-59-A oligomers, which are bound by latent RNase L
monomers, driving the dimerization and activation of RNase L.
Activated RNase L cleaves single-stranded RNA, 39 of U-A and
U-U sites found in both viral and cellular RNA. RNase L
endoribonuclease activity is thus not limited to viral RNA, but also
degrades host cell RNA, including ribosomal RNA. As OAS genes
are stimulated by IFN-a/b, elevated OAS levels enhance the anti-
viral state in adjacent, non-infected cells responding to IFN-a/b.
Nevertheless, inappropriate activation of RNase L is counterbal-
anced by the unstable nature of 29-59A oligomers and the
endogenous RNase L inhibitor, RL1 [6]. A novel aspect of the
OAS/RNase L pathway is the cleavage of host RNA releasing free
39-monophosphates that can activate the cytoplasmic RNA
helicases RIG-I and Mda-5 [7]. Recognition by these pattern
recognition receptors initiates IFN-b transcription, similar to the
activation mediated by recognition of specific viral RNA
structures. RNase L thus not only exerts anti-viral effects via
RNA degradation and apoptosis, but also has the capacity to
amplify and prolong expression of anti-viral genes and other ISGs.
The anti-viral activity of the OAS/RNase L system has been
studied in several virus infections in vitro and in vivo [3,4]. Protective
mechanisms of the OAS/RNase L pathway are generally more
evident for RNA relative to DNA virus infections. However, the
contribution of RNase L to disease severity and viral control varies
significantly depending on the virus and even virus strain studied,
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anti-viral mediators. For example, encephalomyocarditis virus
(EMCV) replication was only modestly increased in RNase L
deficient (RL
2/2) mouse embryonic fibroblasts, consistent with
enhanced susceptibility to infection in vivo. Although RNase L
prolonged survival, mortality rates of infected RL
2/2 and control
mice were similar. Furthermore, IFN-b treatment increased the
survival time of infected wild-type (wt) and to a lesser extent
RL
2/2 mice, indicating that alternate IFN-dependent anti-viral
mechanisms act in the absence of RNase L [8]. In contrast, the
requirement for RNase L activity to protect from another
picornavirus, Coxsackievirus B4, was evident by significantly
increased mortality rates of infected RL
2/2 compared to wt
mice. However, increased mortality was not the result of
uncontrolled virus replication, as virus titers were only slightly
elevated within pancreatic islet cells in vivo. By contrast, pancreatic
islet cells derived from RL
2/2 mice, treated with IFN-a and
infected in vitro exhibited increased virus replication and loss of
cellular integrity, compared to IFN-a treated RNase L sufficient
cells [9]. These results revealed distinct differences in direct anti-
viral functions of RNase L in vitro and in vivo. Cell type specific
effects of anti-viral RNase L activity are also clearly evident from
studies with West Nile virus (WNV). While mouse embryonic
fibroblasts display RNase L dependent anti-viral activity [10],
IFN-b treatment revealed no affect of RNase L in reducing WNV
replication in either cortical or peripheral motor neurons [11].
Nevertheless, a modest effect was observed in bone marrow
derived macrophages, consistent with increased viral burden in
CD11b
+ splenocytes derived from RL
2/2 compared to wt mice
[11]. Furthermore, increased mortality of RL
2/2 mice in response
to peripheral WNV infection correlated with increased replication
in lymphoid tissue, but not enhanced viral dissemination into the
CNS. A minor role for RNase L in control of WNV in the CNS
was supported by similar viral titers in brains as well as kinetics
and rates of mortality following intracranial infection of RL
2/2
and wt mice. Although viral replication was only transiently
increased in spinal cords of intracranially infected RL
2/2 mice,
the most prominent effect was increased spread to the spleen and
liver [11]. The more critical role of RNase L in limiting WNV
spread in peripheral tissues rather than the CNS highlights the
complexities of OAS/RNase L mediated anti-viral mechanisms in
vivo.
IFN-a/b mediated innate responses are also essential to control
virus replication and survival following coronavirus infections [12–
15]. Infections in vitro and in vivo induce upregulation of IFN-a/b
and anti-viral mediators, including PKR and OAS [12,16,17];
however, the participation of these pathways in the anti-viral
response to CNS infection has not been elucidated. In vitro, the
dual liver and neurotropic MHV-A59 strain does not elicit
degradation of 18S and 28S ribosomal RNA, suggesting the
absence of RNase L activation in HELA cells [18]. However,
administration of an RNase L agonist inhibited replication of the
hepatotropic MHV-3 strain in peritoneal macrophages in vitro and
in liver in vivo [19]. Nevertheless, reduced viral replication via
RNase L function in vivo was insufficient to prevent liver necrosis
and death. The nonlethal gliotropic JHM strain of mouse hepatitis
virus (MHV-JHM) replicates exclusively in the CNS following
intracranial infection and is controlled by both innate and
adaptive responses [20,21]. CNS infection results in a non-lethal
encephalitis with immune-mediated demyelination resulting in
hind limb paralysis [21]. Based on expanded tropism to
hippocampal neurons and widespread dissemination within the
CNS of mice deficient in IFN-a/b signalling (IFNAR
2/2) [12],
the gliotropic MHV-JHM variant was used to probe an anti-viral
role of RNase L within the CNS. While the vast majority of wt
mice survived, RL
2/2 mice succumbed to infection, albeit delayed
compared to IFNAR
2/2 mice. Although enhanced morbidity
suggested a prominent role of RNase L in anti-viral protection, the
absence of RNase L neither diminished overall virus control in the
CNS, nor enhanced neuronal infection. Furthermore, RL
2/2
mice did not reveal any impairment in IFN-a/b induction,
alterations in proinflammatory cytokines or inflammation com-
pared to wt mice. These data rather reveal a novel role of RNase L
in specifically counteracting focal microglia/macrophage infec-
tion, thus potentially sustaining microglia mediated neuroprotec-
tive effects and ameliorating demyelination.
Results
RNase L deficiency increases morbidity without affecting
virus control
Mice deficient in IFN-a/b signalling succumb to an otherwise
sub-lethal gliotropic MHV-JHM within 8 days of infection despite
functional CD8 T cell responses [12]. Uncontrolled viral
replication in the absence of IFN-a/b implicated a crucial role
of anti-viral innate mechanisms in stemming viral spread within
the CNS. To elucidate the role of RNase L in CNS pathogenesis,
gliotropic MHV-JHM infection was examined in RL
2/2 mice [8].
Increased susceptibility of RL
2/2 mice was evident by more
severe clinical symptoms of acute encephalitis at 9–11 days post
infection (p.i.) (Fig. 1, top panel). With the exception of increased
severity, onset and progression of clinical symptoms in infected
RL
2/2 were similar to those exhibited by infected wt mice. These
included initial symptoms of acute viral encephalitis, including:
lethargy, dehydration and weight loss, which progressed to
diminished hind limb function. Furthermore, mortality rates were
significantly higher in RL
2/2 mice, with over 90% succumbing to
infection by 12 days p.i. (Fig. 1, middle panel), approximately 3–4
days delayed relative to IFNAR
2/2 mice [12]. Assessment of
direct anti-viral functions of RNase L [9,11] revealed no
Author Summary
Initial spread of viruses is controlled by type I interferon
induced antiviral molecules. Early intervention with viral
replication is especially critical in central nervous system
infections to reduce loss of non-renewable cells and
mitigate immune pathology. One of the best characterized
anti-viral mechanisms is mediated by ribonuclease L
(RNase L). RNase L exerts activity at multiple levels,
including degradation of viral and host RNA, induction of
apoptosis, and propagation of the IFN-a/b pathway.
Recent studies suggest that RNase L antiviral activity is
dependent on the virus, as well as the cell type and tissue
infected. This study demonstrates that RNase L protects
mice infected with a sub-lethal, demyelinating neurotropic
coronavirus by ameliorating encephalitis and morbidity,
albeit without affecting control of infectious virus or IFN-a/
b expression. RNase L specifically protected the brain stem
from sustained infection and prevented spread of virus to
microglia/macrophages located in spinal cord grey matter.
The subtle regional alteration in tropism in the absence of
RNase L coincided with increased apoptotic cells and
earlier onset as well as increased severity of axonal
damage and demyelination. The results demonstrate
how subtle regional alterations in viral tropism within
the CNS may severely affect the balance between
neuroprotection and neurotoxicity mediated by microg-
lia/macrophages.
RNase L Protects Mice from Demyelination
PLoS Pathogens | www.plospathogens.org 2 October 2009 | Volume 5 | Issue 10 | e1000602significant changes of infectious virus in brains of RL
2/2,
compared to wt mice. Virus titers were increased less than 0.5
log10 in RL
2/2 mice (Fig. 1, bottom panel). Very modest anti-viral
RNase L activity in the CNS was confirmed by analysis of viral
RNA from CNS tissue. Levels of viral mRNA encoding the viral
nucleocapsid protein were increased less than 2.4-fold in spinal
cords of RL
2/2 compared to wt mice at any time point (Table 1).
As liver may constitute an extraneural infection site in immuno-
compromised mice, viral replication in this tissue was also assessed
by real-time PCR. The abundant viral mRNA encoding the
nucleocapsid protein was detected in liver at very low levels
compared to the CNS in both groups, albeit only at early time
points (Table 1). Although viral RNA was elevated in livers of
RL
2/2 mice at day 7 p.i., clearance by day 10 p.i. suggested
hepatitis did not contribute to mortality. Necrotic foci were not
evident in either mouse group by gross examination. A minor role
of RNase L in viral control in vivo was reminiscent of the previously
described picornavirus models [8,9,11].
RNase L deficiency does not impair type I IFN responses
in the CNS
In addition to RNA degradation, RNase L also induces a
multitude of genes in the IFN-a/b pathways during infections with
Sendai virus and EMCV [7]. Thus, both self and virus small RNA
products released by RNase L activate cytoplasmic RNA helicases
RIG-I and Mda-5 to optimize and perpetuate anti-viral responses.
However, IFN-a and IFN-b expression levels were slightly
increased, rather than decreased in brains of MHV-JHM infected
RL
2/2 mice relative to wt mice (Fig. 2). Furthermore, OAS-2,
IFIT-1, IFIT-2, and IRF-7, representing prominently activated
ISGs, were induced to similar, or modestly increased levels in the
CNS of infected RL
2/2 mice. Slightly enhanced IFN-a/b and
ISG expression was also observed in spinal cords from infected
RL
2/2 relative to wt mice (data not shown). Consistent with
similar virus replication and control in the CNS, neither IFN-a/b
nor the expression of downstream ISGs were impaired at the tissue
level. These data suggest that a positive RNase L-dependent
feedback loop in propagating IFN-a/b signalling is not activated
during MHV-JHM infection in the CNS.
RNase L does not alter CNS inflammatory responses
An unanticipated feature of RL
2/2 mice is delayed tissue
rejection in transplant studies [22], suggesting a role of RNase L in
modifying antigen presentation, lymphocyte trafficking or func-
tion. To assure that altered pathogenesis was not due to differential
inflammatory responses, the CNS was examined for extent,
composition and localization of infiltrating cells. Characterization
of cells recruited to the CNS using flow cytometry revealed similar
total numbers of infiltrating cells and no alterations in their
composition (Fig. 3). Unlike IFNAR
2/2 mice [12], neutrophil
infiltration was not affected in RL
2/2 mice and macrophages
comprised the most prominent population early p.i. in both
Figure 1. RNase L ameliorates clinical symptoms and is
required for recovery from MHV-JHM. Top Panel: Morbidity of
wt and RL
2/2 mice infected with gliotropic MHV-JHM. Data are the
average of two independent experiments. Middle Panel: Survival rates
of wt and RL
2/2 (n=16/group) following i.c. infection with MHV-JHM.
Data are representative of two independent experiments. Bottom
Panel: Virus replication in the brains of infected mice is not significantly
altered by RNase L deficiency (n=6/group).
doi:10.1371/journal.ppat.1000602.g001
Table 1. Levels of viral nucleocapsid protein encoding mRNA
in CNS and liver.
Day p.i. Spinal cord Liver
wt RL2/2 wt RL2/2
49 . 0 62 3.062
5 794
a644
b 10856215
60 . 5 6.03 6.06.05
7 17696125 31486363
10 6136184 3536124 BD
c BD
arelative to GAPDH.
bSD from 3 individual mice.
cbelow detection.
doi:10.1371/journal.ppat.1000602.t001
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+ and CD8
+ T cells peaked to nearly identical
numbers at day 7 p.i. in both groups. Furthermore, CNS
infiltrating CD8
+ T cells in both groups were comprised of 50%
and 60% virus specific cells at day 7 and 10 pi, respectively, as
monitored by D
b/S510 class I tetramer staining [23]. Similarly, no
significant differences in the extent of inflammatory cells were
observed by histochemical analysis (data not shown). These data
confirm that priming and trafficking of virus specific T cells was
unaffected by the loss of RNase L activity, consistent with effective
clearance of infectious virus.
RNase L protects the brain stem from sustained MHV-
JHM infection and apoptosis
RNase L did not overtly affect overall CNS viral replication;
however, it may act in a tissue or cell type specific manner [11].
MHV-JHM initially infects ependymal cells and spreads to
astrocytes, microglia/macrophages and predominantly oligoden-
drocytes, but rarely infects neurons [24]. However, MHV-JHM
induced mortality in the absence of IFN-a/b signalling is
associated with a dramatically expanded virus tropism to
hippocampal neurons [12]. To assess the possibility that RNase
L exerts cell type dependent anti-viral effects not apparent from
whole tissue homogenates, the distribution of virus infected cells
was analysed by immunohistochemistry. Sequential analysis
demonstrated a limited infection of neurons within the brain with
a predominance in the brain stem at day 5 p.i. in both RL
2/2 and
wt mice (Fig. 4). Glia tropism prevailed in both groups and overall
distribution of virus infected cells was similar with occasional
neurons still infected at day 7 p.i. (data not shown). By day 10 p.i.
virus infected cells declined in cortex and brain stem of both wt
and RL
2/2 mice. However, in contrast to wt mice which had
cleared virus from brain stem, virus infected cells were sustained in
the brain stem of RL
2/2 mice and were predominantly microglial
in appearance (Fig. 4). The overall extent and distribution of viral
infected cells was thus similar during peak virus replication in
brains of RL
2/2 and wt mice, with the exception of sustained
Figure 2. RNase L does not alter IFN responses to MHV-JHM infection of the CNS. Expression of IFN-a4, IFN-b1, OAS2, IFIT-1, IFIT-2 and IRF-
7 mRNA relative to the housekeeping gene GAPDH in brains of MHV-JHM infected wt and RL
2/2 mice. Data are the average of individual mouse
brains from two independent experiments (n=6).
doi:10.1371/journal.ppat.1000602.g002
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experiments indicate that these cells are microglia or macrophage/
monocytes (see below). These data contrast with the infection of
IFNAR
2/2 mice [12] which show predominant neuronal
infection. Therefore, preferential infection of neurons could not
account for the increased mortality in RL
2/2 mice. The data also
indicated that protective RNase L functions are not overtly
reflected in early anti-viral activity but are manifested in region
specific protection.
RNase L activation leads to apoptosis and elimination of
infected cells, a process requiring activated caspase 3 [3,25].
Furthermore, IFNa/b mediated activation of RNase L also
induces apoptosis in non-infected cells [8]. During MHV-JHM
infection of wt mice the majority of apoptotic cells are lymphocytes
[26], which are not targets of infection. Although oligodendrocyte
apoptosis has been linked to the demyelinating process, the
demonstration of apoptotic oligodendrocytes during MHV-JHM
infection has been elusive [27,28]. The retention of virus infected
cells in brain stem may result in enhanced local T cell activation
and apoptosis of either T cells, infected cells, or both. Therefore,
the frequency of apoptotic cells was examined at day 10 p.i. In
contrast to the brain stems of wt mice which contained few
apoptotic cells, apoptotic cells were prominent in brain stems of
RL
2/2 mice (Fig. 4) coincident with retention of virus infected
cells. Although increased focal virus infection associated with
substantially increased apoptotic cells presumably dysregulates
neuronal function and potentiates tissue damage, there was no
evidence that apoptotic cells are preferentially located adjacent to
neurons.
RNase L ameliorates demyelination and axonal damage
Sustained brain stem infection and apoptosis in RL
2/2 mice
coincided with increased morbidity and mortality, despite similar
overall control of viral replication. The morbidity in MHV-JHM
Figure 3. RNase L does not alter CNS inflammation. Numbers and composition of CD45
hi inflammatory cells derived from brains of infected wt
and RL
2/2 mice analyzed by flow cytometry at the indicated times p.i. Numbers of bone marrow derived CD45
hi cells/brain are shown in the top left
panel. Composition of cell infiltrates is indicated by relative percentages of Ly-6G
+ neutrophils (ND=not detected), F4/80
+ macrophages, CD4 T cells,
and CD8 T cells. Percentages of virus-specific CD8 T cells within the CD8 population is assessed by D
b/S510 tetramer staining (CD8+Tet+). Data are the
mean of two independent experiments6SEM.
doi:10.1371/journal.ppat.1000602.g003
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2/2 mice also coincided temporally with the onset of
acute primary demyelination in wt mice. RL
2/2 mice were thus
examined for enhanced tissue pathology and demyelination. Brain
stems of infected wt mice revealed minimal demyelination by day
10 p.i. (Fig. 5). By contrast, demyelination was more severe in
brain stems of RL
2/2 mice, correlating with increased numbers of
virus infected as well as apoptotic cells. Demyelination is associated
with a variable degree of axonal damage [29,30]. Primary immune
mediated demyelination in the spinal cord during MHV-JHM
infection coincides with early axonal degeneration [31,32]. While
axons were largely intact in brain stems of wt mice, axonal
integrity within demyelinated lesions was severely compromised in
RL
2/2 mice as indicated by a striking decrease in neurofilament
and an increase in dystrophic axons within lesions (Fig. 5).
In spinal cords of wt mice, demyelination was also minimal at day
7 p.i. and increased by day 10 p.i. (Fig. 6), when control of virus
replication is clearly evident (Table 1). By contrast, large focal areas
of severe demyelination were already apparent in RL
2/2 mice at
day 7 p.i., resembling those in wt mice at day 10 p.i. In addition to
the accelerated kinetics of demyelination, the severity of myelin loss
was more pronounced inthe absence of RNase L at both days 7 and
10 p.i. Consistent with the more rapid loss of myelin in infected
RL
2/2 mice, quantification of demyelinated areas at day 7 p.i.
revealed 1.260.8% demyelination in spinal cords of wt mice and
3.061.7% in RL
2/2 mice. Increased demyelination in both brain
stem and spinal cord are thus a hallmark of infected RL
2/2 mice,
irrespective of overall viral control.
Apoptotic cell numbers and axonal damage in the spinal cords
of RL
2/2 mice were also evaluated to determine an association
with increased demyelination. In wt mice, apoptotic cells were
undetectable in spinal cord at day 7 p.i. (data not shown), but were
prominent in white matter by day 10 p.i. (Fig. 7). By contrast,
spinal cords from RL
2/2 mice already exhibited small areas of
apoptotic cells at 7 days p.i., albeit only in white matter. However,
by day 10 p.i. numerous apoptotic cells were evident in both white
matter and grey matter of spinal cords from infected RL
2/2 mice.
Furthermore, in contrast to brain stems, apoptotic cells were often
detected in close proximity to neurons (inset Fig. 7); however, there
Figure 4. RNase L does not alter the extent of neuronal infection but delays viral clearance from brain stem. Viral nucleocapsid antigen
detected by immunoperoxidase staining using mAb J.3.3 in brains from infected wt and RL
2/2 mice at days 5 and 10 p.i. (top panels: brown
chromogen; hematoxylin counterstain). Note neuronal infection (arrows) and similar foci of viral antigen in glial cells in brain stem at day 5 p.i. By day
10 p.i. infection is controlled in wt mice, but foci of infected non neuronal cells with glia morphology are sustained in RL
2/2 mice. Scale bar=100 mm.
Immunohistochemical staining for activated caspase-3 (bottom panels) at day 10 p.i. indicates increased numbers of cells undergoing apoptosis in
brain stem of RL
2/2 relative to wt mice. Scale bar=100 mm.
doi:10.1371/journal.ppat.1000602.g004
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the absence, rather than presence, of RNase L contributes to
enhanced apoptosis in white matter, and subsequently also in grey
matter.
Analysis of axonal integrity revealed that all axons were intact in
spinal cords of wt mice consistent with minimal demyelination at
day 7 p.i. (Fig. 7). By contrast, a striking decrease in neurofilament
and an increase in dystrophic axons within demyelinated lesions
Figure 5. Increased demyelination and axonal damage in brain stem. Brain stems of infected wt and RL
2/2 mice at day 10 p.i. stained with
Luxol Fast Blue (top panels). Scale bar=100 mm. Immunohistochemical staining for axonal integrity in brain stem at day 10 p.i. (bottom panels) Scale
bar=100 mm. Note more abundant loss of myelin and axonal degeneration in infected RL
2/2 relative to wt mice.
doi:10.1371/journal.ppat.1000602.g005
Figure 6. RNase L mitigates spinal cord demyelination. Spinal cords of infected wt and RL
2/2 mice at day 7 (top) and day 10 (bottom) p.i.
stained with Luxol Fast Blue. Scale bar=100 mm.
doi:10.1371/journal.ppat.1000602.g006
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matter of RL
2/2 mice by day 7 p.i. At day 10 p.i. the amount of
axonal degeneration in wt mice resembled that of RL
2/2 mice at
day 7 p.i., consistent with the severity of demyelination. However,
by day 10 p.i. spinal cords of RL
2/2 mice showed marked axonal
loss located in areas of myelin loss (Fig. 7), similar to results in
brain stem. The increased pathological changes in both brain stem
and spinal cord thus correlated with the high mortality rates of
RL
2/2 mice starting at day 9 p.i.
RNase L prevents viral spread to grey matter microglia/
macrophages in spinal cords
The inability to directly link increased axonal damage with
enhanced neuronal infection remains puzzling and supports
dysregulation of oligodendrocyte function and/or neuroprotective
functions of microglia as contributing factors to the severe
pathological phenotype and clinical outcome. Increased demye-
lination in spinal cords has been correlated with the extent of white
and grey matter infection in mice infected with heterologous
MHV strains [33]. Furthermore increased apoptosis, specifically in
spinal cord grey matter of RL
2/2 mice supported grey matter
infection. Increased demyelination as well as apoptosis in grey
matter in RL
2/2 mice thus prompted a more detailed
investigation of viral antigen distribution in spinal cords, where
the demarcation between grey and white matter is linear as
opposed to the more complex organization of brain stem.
Neuronal infection was not observed in spinal cords of either
RL
2/2 or wt mice. Furthermore, the number of infected cells with
oligodendrocyte morphology in the white matter of RL
2/2 mice
was similar to wt mice at day 7 p.i. (Fig. 8). However, a prominent
difference in viral antigen positive cells was noted in spinal cord
grey matter. RL
2/2 mice harboured several foci of infected cells
with microglia morphology, whereas viral antigen positive cells
were rarely observed in spinal cord grey matter of wt mice (Fig. 8).
Furthermore, a large number of infected cells in the grey matter of
RL
2/2 mice were identified as microglia and/or infiltrating
monocytes based on co-localization with Iba-1 positive cells (Fig. 9).
Foci of Iba-1 positive cells co-expressing viral antigen in the grey
matter were only observed in RL
2/2 but not wt mice, confirming
results obtained by immunohistochemistry (Fig. 8). Nevertheless,
infected Iba-1 positive cells were dispersed throughout the white
matter of wt and RL
2/2 mice. Similar characterization of the
brain stem at day 10 p.i. also identified Iba -1 positive cells as
prominent cells harbouring sustained viral infection (data not
shown). Co-stains with the astrocyte specific marker GFAP showed
no evidence of infected astrocytes in spinal cord grey matter;
Figure 7. RNase L regulates apoptosis and ameliorates axonal degeneration. Immunohistochemical staining for activated caspase-3 (top
panels) at day 10 p.i. indicates apoptosis in grey matter (above line) of spinal cords from RL
2/2 mice, but not wt mice. Scale bar=50 mm. Inset shows
a large neuron (arrow) surrounded by five apoptotic cells. Scale bar=20 mm. Immunohistochemical staining for axonal integrity at day 7 (middle
panels) and day 10 (bottom panels) p.i. in spinal cord white matter. Note earlier and more abundant loss of axonal integrity in spinal cords from
infected RL
2/2 relative to wt mice. Scale bar=100 mm.
doi:10.1371/journal.ppat.1000602.g007
RNase L Protects Mice from Demyelination
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RL
2/2 mice (data not shown). These data indicate that RNase L
mediated antiviral function acts specifically in microglia and/or
monocytes. Moreover the focal nature of infection in grey matter
suggests microglia localization is associated with enhanced
susceptibility to infection in the absence of RNase L.
To determine whether infection of Iba-1 positive cells was
biased to microglia or infiltrating monocytes, both cell populations
were purified from spinal cords of infected mice by fluorescence
activated cell sorting. Measurement of viral mRNA encoding the
nucleocapsid protein revealed that microglia derived from RL
2/2
mice harbored 3.0-fold higher levels of viral RNA at day 7 p.i.,
while the relative levels in monocytes was only increased 1.6-fold
relative to infected wt mice (Table 2). However, viral mRNA levels
decreased in both cell types reaching comparable levels by day 10
p.i. While RNA levels for TNF were elevated in RNase L deficient
microglia and monocytes by 2-fold and 1.4 fold, respectively,
iNOS levels remained similar relative to wt derived cells (data not
shown). IFNc relative to GAPDH mRNA levels in spinal cord
were also modestly increased from 4.660.5 in wt mice to 8.160.3
in RL
2/2 mice at the peak (day 7 p.i.) and declined to 1.460.4
and 1.260.1, respectively, by day 10 p.i., confirming a modest
contribution of proinflammatory cytokines to pathogenesis.
Moderately increased viral RNA levels in microglia are thus
consistent with foci of microglia infection in spinal cord grey
matter not present in wt mice.
Overall these data demonstrate that accelerated and enhanced
demyelination in the absence of RNase L coincided with
significant neuronal damage in the absence of expanded neuronal
infection. Furthermore, the limited extent of increased focal glial
infection appeared insufficient to mediate the pathological effect.
To assess potential differences in the overall activation state of
microglia, the distribution and morphology of Iba-1 positive cells
was assessed in spinal cord grey matter. Microglia in wt mice were
activated as demonstrated by their intense staining and ramified
phenotype and localized in close proximity to neuronal cell bodies
(Fig. 10). By contrast, in infected RL
2/2 mice, fewer microglia
were activated based on their Iba-1 staining and morphology and
did not show preferential association with neurons. Whether the
absence of RNase L itself or infection of microglia mitigates a
neuroprotective function of microglia remains to be explored. The
notion that inflammatory insults disrupt neuroprotective functions
by microglia is based on microglia mediated neuroprotection in
models of injury and LPS preconditioning [34–36] and loss of
protection following viral infection [37].
Discussion
IFN-a/b dependent innate immunity is essential to contain viral
spread during most viral infections prior to control by adaptive
responses. Nevertheless, the in vivo anti-viral effector mechanisms
contributing to innate viral control remain poorly understood. The
best characterized pathways are mediated by activation of PKR
and RNase L [3–5]. However, in contrast to the conclusive effects
of PKR and RNase L deficiency on viral replication in vitro, in vivo
studies demonstrate more subtle anti-viral effects [8,9,11]. During
WNV infection, RNase L deficiency is manifested in profoundly
altered morbidity, despite similar viral control after footpad
inoculation [11]. IFN-a/b-mediated anti-viral responses are also
critical for controlling spread of neurotropic coronavirus within
glial cell populations and preventing infection of neurons [12].
Based on its activation by numerous RNA viruses, RNase L was
investigated as a prototypical anti-viral effector molecule in
controlling MHV-JHM virus replication in the CNS.
RNase L deficiency was not sufficient to duplicate uncontrolled
replication and the rapid uniform lethality observed in IFNAR
2/2
mice [12]. Nevertheless, a critical contribution to virus suscepti-
bility was demonstrated by a significant increase in both clinical
disease and mortality. Mortality was delayed by 3–4 days in
RL
2/2 relative to IFNAR
2/2 mice, but could not be attributed to
uncontrolled viral replication or spread to neurons. In fact, overall
virus replication in brains and spinal cords of RL
2/2 mice was
only modestly increased and declined with kinetics similar to wt
mice. These latter findings were reminiscent of transiently
increased viral replication in the CNS of RL
2/2 mice following
intracerebral WNV inoculation [11].
In addition to direct anti-viral activities, activated RNase L
degrades viral and host RNA [38,39]. The cleavage products may
Figure 8. RNase L prevents spread of MHV-JHM to spinal cord grey matter. Viral antigen in spinal cords from infected wt and RL
2/2 mice at
day 7 p.i. Note spread of virus into the grey matter (GM) (arrows, bottom panel) is only observed in RL
2/2 mice, whereas viral antigen is restricted to
white matter (WM) in wt mice. Also note the absence of infected neurons. Scale bar=50 mm.
doi:10.1371/journal.ppat.1000602.g008
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receptors, propagating the expression of IFN-a/b and ISGs [7].
While this function of RNase L is indeed evident by reduced IFN-
b production in EMCV infected RL
2/2 mice [7], MHV-JHM
infection of the CNS presented no evidence for this pathway. The
negligible affects of RNase L deficiency on overall viral replication
Figure 9. RNase L protects microglia/macrophages from infection in grey matter. Virus infected cells detected using virus nucleocapsid
protein specific mAb J.3.3 (Antigen - green) and macrophage/microglia cell marker Iba-1 (Iba-1 – red) in spinal cords from infected wt and RL
2/2 mice
at day 7 p.i. Co-localization of viral antigen and Iba-1 staining cells (Merge - yellow) indicates infected microglia/macrophages are present only in
white matter (WM) of wt, but both white matter and grey matter (GM) in RL
2/2 spinal cords. Scale bar=100 mm.
doi:10.1371/journal.ppat.1000602.g009
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infection in the CNS does not, or only sparsely, activates OAS/
RNase L activity in vivo. This finding is reminiscent of in vitro
studies with the heterologous MHV-A59 strain [26]. Nevertheless,
the preferential susceptibility of RNase L deficient microglia/
monocytes to MHV-JHM infection demonstrates that viral RNA
does activate cellular RNA sensors, albeit in a cell type specific
manner. This is supported by Mda-5 triggered activation of the
IFN-a/b pathway in microglia and macrophages infected with
MHV-A59 in vitro [17]. Whether the apparent inability of
gliotropic MHV-JHM to activate RNase L in other cell types in
vivo resides in distinct basal OAS/RNase L expression levels,
activation of distinct OAS enzymes, or other RNA sensing
receptors such as Mda-5 has not been elucidated.
Numerous functions of RNase L, not directly associated with
anti-viral activity, may contribute to the increased susceptibility of
RL
2/2 mice to MHV-JHM infection. RNase L plays a role in
translational inhibition, regulation of mRNA stability, apoptosis,
proliferation and tumor suppression [25,40]. For example, RNase
L contributes to IFN-a/b mediated apoptosis, as well as
homeostasis of thymocytes and splenocytes in young naı ¨ve mice
[8]. RNase L deficiency also delays tissue graft rejection [22]
implicating a defect in T cell function or trafficking. Nevertheless,
both histochemical and flow cytometric analysis revealed a similar
extent and composition of inflammatory cells in the CNS of
infected RL
2/2 and wt mice. The lack of RNase L mediated
alterations in T cells was supported by similar peripheral
expansion of virus-specific CD8 T cells and kinetics of viral
control. Increased morbidity could thus not readily be attributed
to altered inflammation or pro-inflammatory signals at the tissue
level.
Neuronal infection by gliotropic MHV-JHM is sparse and only
evident early p.i. in wt mice. No evidence for enhanced neuronal
infection in RL
2/2 mice thus suggested that the IFN-a/b
mediated anti-viral mechanisms in neurons are RNase L
independent. This contrasts with a protective role for RNase L
in inhibiting HSV-1 replication in neurons of IFN-b treated
trigeminal ganglia [41], and supports virus specific susceptibilities
to innate anti-viral immunity. Distinguishing features in MHV-
JHM infected RL
2/2 mice are the sustained areas of microglia
infection in brain stem and focal areas of infected microglia within
the spinal cord grey matter. Infected cells in spinal cord grey
matter are also evident in SCID [42] and IFNAR
2/2 mice
(unpublished observation) following infection with the gliotropic
MHV-JHM. In RL
2/2 mice the prominent infected cells in brain
stem and spinal cord grey matter were identified as Iba-1 positive
microglia or infiltrating monocytes, which cannot readily be
distinguished by immunohistochemistry. Nevertheless the mor-
phology of infected cells in the grey matter was consistent with
activated microglia, rather than the monocyte/macrophages with
dense cytoplasm found prominently in demyelinating lesions.
Furthermore, preferential microglia infection was supported by a
relatively greater increase of viral RNA in microglia relative to
monocytes, when comparing RL
2/2 versus wt mice. The
prominent location of Iba-1 positive cells in grey matter of
RL
2/2 mice could not be attributed to the absence of activated
microglia in grey matter of wt mice. In fact, microglia in wt mice
exhibited a more ramified phenotype surrounding neurons
compared to microglia in RL
2/2 infected mice. It remains
unclear whether abrogation of the proximal localization of
microglia to neurons in RL
2/2 spinal cords reflects an unknown
function of an RNase L enhanced neuroprotective effect, or
altered function due to infection.
Surprisingly, both prolonged brain stem infection and enhanced
spinal cord grey matter infection was associated with more severe
demyelination and axonal damage. Overall, the CNS pathology
characteristic of MHV-JHM infection was accelerated by 3–4 days
in RL
2/2 relative to wt mice. Although infection of microglia
correlated with a subsequent increase in apoptotic cells, apoptotic
cells surrounding neurons were only evident in spinal cord, not in
brain stem. The inability to detect increased numbers of infected
or apoptotic cells in spinal cord white matter is consistent with
both an apparent lack of RNase L activation in oligodendrocytes
during MHV-JHM infection and paucity of apoptotic oligoden-
drocytes in wt mice [28].
Whether apoptotic cells originated from infected myeloid cells
themselves or from lymphocytes migrating to the infected areas
Table 2. Levels of viral nucleocapsid protein encoding mRNA
in cell populations purified from spinal cords.
Day p.i. Microglia Monocytes
wt RL2/2 wt RL2/2
7 198
a625
b 5776204 79614 126645
10 47624 60627 27613 4 61
arelative to GAPDH.
bSD from two sorting experiments with pooled samples from n=8 per group
and time point.
doi:10.1371/journal.ppat.1000602.t002
Figure 10. RNase L enhances microglia activation. Microglia activation in spinal cords from infected wt and RL
2/2 mice at day 7 p.i. Microglia/
monocytes detected by immunoperoxidase staining using anti Iba-1antibody.
doi:10.1371/journal.ppat.1000602.g010
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showed no co-localization of activated caspase 3 and Iba-1 (data
not shown). Overall, the neurologic disability and morbidity of the
infected RL
2/2 mice appears to result from axonal or neural
degeneration, independent of neuronal infection in both brain
stem and spinal cord. The enhanced demyelination phenotype is
thus distinct from demyelination attributed to enhanced white
matter infection by recombinant neuronotropic MHV variants
[33]. RNase L deficiency and infection of microglia may
contribute to this pathology in several ways. Infection in the
absence of RNase L may impair neuroprotective effects exerted by
microglia under inflammatory conditions [34–36]. Alternatively,
enhanced infection of microglia may increase proinflammatory
responses resulting not only in enhanced recruitment of T cells and
monocytes, but also increased local production of neurotoxic
factors such as TNF, nitric oxide, oxidative radicals, and matrix
metalloproteases. However, only modest increases in IFNc mRNA
in spinal cord, as well as minor differences in TNF and iNOS
mRNA in microglia/monocytes suggest these effects may only be
apparent at a focal level. Increased localized T cell effector
function, manifested in release of perforin and granzymes, has also
been shown to contribute to axonal injury without affecting
demyelination [30]. Lastly, RNase L deficient and/or infected
microglia may perturb normal microglia functions in maintaining
neuronal health as indicated by disruption of neuronal autophagy
by SIV infected microglia [37]. It thus remains to be determined
to what extent accelerated and more severe pathology is due to
disruption of the neuroprotective functions of microglia and/or
from overt activation due to infected cells [43–47]. Independent of
a pathogenic effect, it is interesting to note that the absence of
RNase L also enhanced macrophage susceptibility to WNV
infection [11]. Whether this reflects differential activation of OAS
enzymes or participation of other pattern recognition receptors
such as Mda-5 in susceptible cell types in vivo remains to be
elucidated.
In summary, these data highlight a novel role of RNase L in
protection from virus induced demyelination. Although RNase L
did not play an overt anti-viral role as measured by viral
replication, it did provide specific protection from focal infection
of microglia/macrophages in the CNS. RNase L was not crucial in
protecting neurons from infection and played no obvious role in
protecting oligodendrocytes or astrocytes. Furthermore, RNase L
deficiency did not alter proinflammatory responses, diminish IFN-
a/b mediated signals, or dampen adaptive immune mediators.
The results rather uncover how subtle local alterations in viral
tropism may affect the balance between neuroprotection and
neurotoxicity mediated by microglia/macrophages.
Materials and Methods
Animals, viruses, and clinical scores
C57BL/6 mice were purchased from the National Cancer
Institute (NCI, Fredrick, MD). C57BL/6-RL
2/2 mice were bred
and housed under pathogen-free conditions in the Biological
Resources Unit of the Cleveland Clinic. All procedures were
performed in compliance with protocols approved by the
Institutional Animal Care and Use Committee. Mice were infected
at 6 weeks of age by intracranial injection with 250 PFU of the
gliotropic MHV-JHM variant V2.2-1 [48] in 30 mL endotoxin-
free Dulbecco’s phosphate buffered saline (DPBS). The severity
of clinical disease was graded as previously described [48]:
1=ruffled fur, 2=slow righting reflex, 3=loss of righting reflex,
4=moribund. Following intraperitoneal administration of
ketamin/xylaxine (100 mg/kg/10 mg/kg), mice were perfused
intracardially with 10 mL DPBS. Brains, spinal cords, spleens,
cervical lymph nodes (CLN) and livers were collected and
processed as described below.
Virus titer and cell isolation
Brains were bisected sagittally. One half-brain and whole spinal
cord from each mouse were homogenized in ice cold Tenbroeck
glass grinders in 4 mL or 2 mL of DPBS, respectively. Homog-
enates were clarified by centrifugation for 7 min at 4006g.
Supernatants were stored at 280uC. Virus in supernatants was
measured by plaque assay on monolayers of delayed brain tumor
(DBT) astrocytoma cells as previously described [48]. CNS cells
from homogenate pellets were resuspended in RPMI containing
25 mM HEPES, adjusted to 30% Percoll (Pharmacia, Upsalla,
Sweden), underlayed with 1 mL 70% Percoll, centrifuged at
8006g for 30 minutes and collected from the 30%/70% Percoll
interface as previous described [23]. Purified CNS cells were
washed and resuspended in RPMI.
Flow cytometry and Fluorescence Activated Cell Sorting
Cell populations isolated from the brain and spinal cord were
phenotyped using four-color flow cytometry. Prior to staining, cells
were incubated with 1% mouse serum and 1% rat anti-mouse
FccIII/IIR monoclonal antibody (mAb) in fluorescent antibody
cell sorting (FACS) buffer (0.5% bovine serum albumin in DPBS)
for 20 minutes at 4uC to block non-specific binding. Cell types
were identified using fluorescein isothiocyanate-, phycoerythrin-,
peridinin-chlorophyll-protein complex- or allophycocyanin-conju-
gated anti-mouse mAb: Ly-6 g (1A8), CD4 (GK1.5), CD8 (53.67)
(all from BD Biosciences, San Diego, CA) and F4/80 (CI:A3-1;
Serotec, Raleigh, NC). Virus specific CD8 T cells were identified
using H-2D
b/S510 MHC class I tetramers as described previously
[23]. Cells were incubated with antibodies for 30 minutes on ice,
washed twice with FACS buffer and fixed with 2% paraformal-
dehyde for 10 minutes on ice. At least 100,000 events were
acquired on a FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA) for subsequent data analysis using Flow-Jo 7 Software
(Tree Star, Inc. Ashland, OR).
For fluorescence activated cell sorting of microglia and
monocyte populations, spinal cords from eight mice per group
were finely minced using a razor blade and dissociated in a 0.25%
trypsin solution as described [27,49] at 37uC for 30 minutes with
periodic tituration. Trypsin was quenched by addition of RPMI
supplemented with 25 mM HEPES and 20% new born calf
serum. The dissociated cells were washed in RPMI containing
25 mM HEPES, 1% FCS, then isolated from the interphase of a
30%/70% percoll gradient as described above. Cells were
incubated with 1% mouse serum and CD16/32 prior to staining
with allophycocyanin-conjugated mAb specific for CD45 (30-F11),
peridinin-chlorophyll protein-conjugated CD11b (M1/70) (BD
Biosciences, San Diego, CA) and phycoerythrin-conjugated mAb
specific for F4/80 (CI:A3-1; Serotec, Raleigh, NC). Monocyte/
macrophages and microglia were purified on a FACSAria cell
sorter (BD Biosciences, San Diego, CA) based on their respective
CD45
hiCD11b
+F4/80
+ and CD45
lo CD11b
+F4/80
+ phenotypes.
Histopathological analysis and fluorescence
immunocytochemistry
One half-brain and whole spinal cords were fixed with formalin
and embedded in paraffin. Sections were stained with either
hematoxylin and eosin or luxol fast blue as described [50].
Distribution of viral antigen was determined by immunoperoxidase
staining (Vectastain-ABC kit; Vector Laboratory, Burlingame, CA)
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nucleocapsid protein as primary antibody, biotinylated horse anti-
mouse as secondary antibody, streptavidin-conjugated horse radish
peroxidise and 3,39-diaminobenzidine substrate (Vector Laborato-
ry) [50]. Similarly, immunoperoxidase staining for neurofilament
used mouse anti-phosphorylated and anti-non-phosphorylated
neurofilament mAb (SMI-31 and SMI-32, Covance, Princeton,
NJ) and immunoperoxidase staining for microglia/macrophages
used anti-ionized calcium-binding adapter molecule-1 antibody
(Iba-1, Abcam, Cambridge, MA). Apoptotic cells were detected by
rabbit anti-activated caspase-3 Ab (Asp175, Cell Signalling
Technology, Beverly, MA). Sections were scored for inflammation,
viral antigen,apoptotic cells, axonaldamage and demyelination in a
blinded fashion. Representative fields-of-view were identified based
on average scores of all sections in each experimental group. For
calculation of the percentage area of demyelination, sections were
digitized and analysed as previously described [27].
To identify infected cell types, spinal cords were embedded in
TissueTek O.C.T. compound (Andwin Scientific, Tryon, NC),
flash frozen in liquid nitrogen and stored at 280uC. Blocks were
warmed to 220uC prior to cutting 10 mm sections by cryostat at
this temperature. Following fixation with 4% paraformaldehyde
for 30 minutes at room temperature, non-specific antibody
binding was blocked using 1% bovine serum albumin, 5% normal
goat serum. Infected cells were identified using anti-MHV-JHM
J3.3 mAb, rabbit anti-glial fibrillary acidic protein antibody
(GFAP, Abcam, Cambridge, MA) and rabbit anti-ionized
calcium-binding adapter molecule-1 antibody (Iba-1, Wako,
Richmond, VA) in combination with goat anti-mouse Alexa-fluor
488 and goat anti-rabbit Alexa-fluor 594-conjugated IgG
(Invitrogen, Carlsbad, CA) as secondary antibodies, respectively.
Sections were mounted with ProLong Gold antifade mounting
media containing 49,6-diamidino-2-phenylindole (Invitrogen,
Carlsbad, CA). Imaging of immunofluorescent sections was
performed with a Leica SP-5 confocal microscope (Leica
Microsystems, Bannockburn, IL). Z-projections of sections were
processed by ImageJ software (National Institutes of Health,
Bethesda, MD)
Real-time PCR
One-half brains and whole spinal cords were snap frozen in
liquid nitrogen and stored at 280uC. Frozen brain or spinal cord
tissue was homogenized in 2 mL and 1 mL Trizol reagent
(Invitrogen, Carlsbad, CA), respectively, in RNase-free Tenbroeck
glass grinders. RNA was purified according to the manufacturer’s
protocol (Invitrogen, Carlsbad, CA). Briefly, 0.2 mL chloroform/
1 mL trizol (Sigma-Aldrich, St. Louis, MO) was added to
homogenate, mixed and centrifuged at 12,0006g for 15 minutes
at 4uC. RNA was precipitated from the aqueous phase by addition
of isopropyl alcohol and centrifugation at 12,0006g for 10 min at
4uC washed in RNase-free 75% ethanol and resuspended in
Ultrapure DNase/RNase-free water (Invitrogen, Carlsbad, CA).
Cells isolated by FACS were immediately resuspended in 400 mL
of Trizol reagent (Invitrogen, Carlsbad, CA) and treated as above.
Isolated total RNA was treated with DNase1, using the DNA-free
kit (Applied Biosystems, Foster City, CA) following the manufac-
turer’s protocol. The concentration and purity of RNA was
measured by spectrophotometry at 260/280 nm. RNA integrity
was confirmed by 1.2% formaldehyde-agarose gel electrophoresis.
Reverse transcription was performed on 2 mg total RNA isolated
from brain and spinal cord or all total RNA isolated from FACS
sorted cells, primed with 250 ng random hexamers, (Invitrogen,
Carlsbad, CA) using MMLV reverse transcriptase (Invitrogen,
Carlsbad, CA) for 50 minutes at 37uC. Real-time PCR was
performed using SYBR Green 26Master Mix (Applied Biosystems,
Foster City, CA) for the following primer sets: Interferon-induced
protein with tetratricopeptide repeats (IFIT)-1: F: 59-CCTTTA-
CAGCAACCATGGGAGA-39, R: GCAGCTTCCATGTGAAG-
TGAC-39; IFIT-2 (ISG-54): F: 59-AGAGGAAGAGGTTGCCT-
GGA-39,R :5 9-CTCGTTGTACTCATGACTGCTG-39; OAS2:
F: 59-AAAAATGTCTGCTTCTTGAATTCTGA-39,R :5 9-TG-
TGCCTTTGGCAGTGGAT-39; JHMV-N: F: 59-TAAGAGT-
GATTGGCGTCG-39,R :5 9-ATTGGGTTGAGTAGTTGCAG-
39; iNOS: F: 59- CCTGGTACGGGCATTGCT-39,R :5 9-CA-
TGCGGCCTCCTTTGAG-39; TNF-a:F :5 9- GCCACCACGC-
TCTTCTGTCT-39,R :5 9- GGTCTGGGCCATAGAACTGAT-
G-39 and for endogenous control, GAPDH: F: 59 -CATGGCC-
TTCCGTGTTCCTA-39,R :5 9-ATGCCTGCTTCACCACCT-
TCT-39. The reaction conditions were: 95uC for 10 minutes,
followed by 40 cycles of: denaturation at 95uC for 10 seconds,
elongation at 60uC for 30 seconds and annealing at 72uC for
30 seconds. IFN-b1, IFN-a4 and IFN-c levels were determined by
realtime PCRusingABIGene Expression Assayswith 26Universal
Taqman Fast Master Mix (Applied Biosystems, Foster City, CA),
using manufacturer default cycling conditions and GAPDH
expression as an endogenous control. All real-time reactions were
run using an ABI 7500fast real-time cycler and analysed with
7500fast software (Applied Biosystems, Foster City, CA). Data
presented are expressed as fold-induction relative to GAPDH based
on the following formula: (2
(CT(GAPDH)-CT(TARGET)))*1000.
Statistical analysis
Students’ t-Test with equal variance was used to compare
RL
2/2 and wt C57BL/6 mice. Significant differences between
groups are noted by: *, =P#0.05.
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